Obesity is associated with changes in oxysterol metabolism and levels in mice liver, hypothalamus, adipose tissue and plasma

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Guillemot Legris, Owein ^a   Mutemberezi, Valentin ^a   Cani, Patrice D ^a   Muccioli, Giulio G ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; OXYSTEROL;

ADIPOSE TISSUE; ANIMAL; BIOLOGICAL MODEL; BLOOD; C57BL MOUSE; GENETICS; HYPOTHALAMUS; LIPID DIET; LIVER; MALE; METABOLISM; MOUSE MUTANT; OBESITY; PHENOTYPE;

ADIPOSE TISSUE; ANIMALS; BILE ACIDS AND SALTS; DIET, HIGH-FAT; HYPOTHALAMUS; LIVER; MALE; MICE, INBRED C57BL; MICE, OBESE; MODELS, GENETIC; OBESITY; OXYSTEROLS; PHENOTYPE;

EID: 84955472393     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19694     Document Type: Article

References (59)

1. Gortmaker, S. L. et al. Changing the future of obesity: science, policy, and action. Lancet 378, 838-847 (2011).
2. Grieve, E., Fenwick, E., Yang, H. C. & Lean, M. The disproportionate economic burden associated with severe and complicated obesity: a systematic review. Obes. Rev. 14, 883-894 (2013).
3. Guh, D. P. et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC. Public Health 9, 88 (2009).
4. Buettner, R., Scholmerich, J. & Bollheimer, L. C. High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity. (Silver. Spring) 15, 798-808 (2007).
5. Fraulob, J. C., Ogg-Diamantino, R., Fernandes-Santos, C., Aguila, M. B. & Mandarim-de-Lacerda, C. A. A Mouse Model of Metabolic Syndrome: Insulin Resistance, Fatty Liver and Non-Alcoholic Fatty Pancreas Disease (NAFPD) in C57BL/6 Mice Fed a High Fat Diet. J. Clin. Biochem. Nutr. 46, 212-223 (2010).
6. Unger, R. H., Clark, G. O., Scherer, P. E. & Orci, L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim. Biophys. Acta 1801, 209-214 (2010).
7. Lupattelli, G., De, V. S. & Mannarino, E. Patterns of cholesterol metabolism: pathophysiological and therapeutic implications for dyslipidemias and the metabolic syndrome. Nutr. Metab Cardiovasc. Dis. 21, 620-627 (2011).
8. Van Rooyen, D. M. et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J. Hepatol. 59, 144-152 (2013).
9. Cerezo, C., Segura, J., Praga, M. & Ruilope, L. M. Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension. Curr. Hypertens. Rep. 15, 196-203 (2013).
10. Hoenig, M. R., Kostner, K. M., Read, S. J., Walker, P. J. & Atherton, J. J. Implications of the obesity epidemic for statin therapy: shifting cholesterol metabolism to a high synthesis and low dietary absorption state. Endocr. Metab Immune. Disord. Drug Targets. 7, 153-166 (2007).
11. Wang, H. & Peng, D. Q. New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids Health Dis. 10, 176 (2011).
12. Leonarduzzi, G., Sottero, B. & Poli, G. Oxidized products of cholesterol: dietary and metabolic origin, and proatherosclerotic effects (review). J. Nutr. Biochem. 13, 700-710 (2002).
13. Brown, A. J. & Jessup, W. Oxysterols and atherosclerosis. Atherosclerosis 142, 1-28 (1999).
14. Murphy, R. C. & Johnson, K. M. Cholesterol, reactive oxygen species, and the formation of biologically active mediators. J. Biol. Chem. 283, 15521-15525 (2008).
15. Lemaire-Ewing, S., Lagrost, L. & Neel, D. Lipid rafts: a signalling platform linking lipoprotein metabolism to atherogenesis. Atherosclerosis 221, 303-310 (2012).
16. Olsen, B. N., Schlesinger, P. H., Ory, D. S. & Baker, N. A. Side-chain oxysterols: from cells to membranes to molecules. Biochim. Biophys. Acta 1818, 330-336 (2012).
17. Vejux, A. & Lizard, G. Cytotoxic effects of oxysterols associated with human diseases: Induction of cell death (apoptosis and/or oncosis), oxidative and inflammatory activities, and phospholipidosis. Mol. Aspects Med. 30, 153-170 (2009).
18. Lordan, S., Mackrill, J. J. & O'Brien, N. M. Oxysterols and mechanisms of apoptotic signaling: implications in the pathology of degenerative diseases. J. Nutr. Biochem. 20, 321-336 (2009).
19. Vaya, J. & Schipper, H. M. Oxysterols, cholesterol homeostasis, and Alzheimer disease. J. Neurochem. 102, 1727-1737 (2007).
20. Jakobsson, T., Treuter, E., Gustafsson, J. A. & Steffensen, K. R. Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol. Sci. 33, 394-404 (2012).
21. Torocsik, D., Szanto, A. & Nagy, L. Oxysterol signaling links cholesterol metabolism and inflammation via the liver X receptor in macrophages. Mol. Aspects Med. 30, 134-152 (2009).
22. Bjorkhem, I. Do oxysterols control cholesterol homeostasis? J. Clin. Invest 110, 725-730 (2002).
23. Murdolo, G. et al. Lipokines and oxysterols: novel adipose-derived lipid hormones linking adipose dysfunction and insulin resistance. Free Radic. Biol. Med. 65, 811-820 (2013).
24. Wooten, J. S. et al. The Influence of an Obesogenic Diet on Oxysterol Metabolism in C57BL/6J Mice. Cholesterol. 2014, 843468 (2014).
25. Tall, A. R. & Yvan-Charvet, L. Cholesterol, inflammation and innate immunity. Nat. Rev. Immunol. 15, 104-116 (2015).
26. Myers, M. G., Jr. & Olson, D. P. Central nervous system control of metabolism. Nature 491, 357-363 (2012).
27. Dieguez, C., Vazquez, M. J., Romero, A., Lopez, M. & Nogueiras, R. Hypothalamic control of lipid metabolism: focus on leptin, ghrelin and melanocortins. Neuroendocrinology 94, 1-11 (2011).
28. Everard, A. et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl. Acad. Sci. USA 110, 9066-9071 (2013).
29. Zamanian, J. L. et al. Genomic analysis of reactive astrogliosis. J. Neurosci. 32, 6391-6410 (2012).
30. Dorfman, M. D. & Thaler, J. P. Hypothalamic inflammation and gliosis in obesity. Curr. Opin. Endocrinol. Diabetes Obes. 22, 325-330 (2015).
31. Mutemberezi, V., Masquelier, J., Guillemot-Legris, O. & Muccioli, G. G. Development and validation of an HPLC-MS method for the simultaneous quantification of key oxysterols. Anal Bioanal. Chem. In Press (2015) doi:10.1007/s00216-015-9150-z.
32. Meljon, A., Wang, Y. & Griffiths, W. J. Oxysterols in the brain of the cholesterol 24-hydroxylase knockout mouse. Biochem. Biophys. Res. Commun. 446, 768-774 (2014).
33. Lund, E. G., Guileyardo, J. M. & Russell, D. W. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. Natl. Acad. Sci. USA 96, 7238-7243 (1999).
34. Li-Hawkins, J., Lund, E. G., Bronson, A. D. & Russell, D. W. Expression cloning of an oxysterol 7alpha-hydroxylase selective for 24-hydroxycholesterol. J. Biol. Chem. 275, 16543-16549 (2000).
35. Mast, N. et al. Cholesterol binding to cytochrome P450 7A1, a key enzyme in bile acid biosynthesis. Biochemistry 44, 3259-3271 (2005).
36. Russell, D. W. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72, 137-174 (2003).
37. McLaughlin, L. A., Dickmann, L. J., Wolf, C. R. & Henderson, C. J. Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening. Drug Metab Dispos. 36, 1322-1331 (2008).
38. Nelson, D. R. et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14, 1-18 (2004).
39. Fuda, H., Javitt, N. B., Mitamura, K., Ikegawa, S. & Strott, C. A. Oxysterols are substrates for cholesterol sulfotransferase. J. Lipid Res. 48, 1343-1352 (2007).
40. Falany, C. N. & Rohn-Glowacki, K. J. SULT2B1: unique properties and characteristics of a hydroxysteroid sulfotransferase family. Drug Metab Rev. 45, 388-400 (2013).
41. Bertolotti, M. et al. Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients. Steroids 73, 1197-1202 (2008).
42. Galman, C., Arvidsson, I., Angelin, B. & Rudling, M. Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood. J. Lipid Res. 44, 859-866 (2003).
43. Iuliano, L. Pathways of cholesterol oxidation via non-enzymatic mechanisms. Chem. Phys. Lipids 164, 457-468 (2011).
44. Tajima, M. et al. Consumption of a high-fat diet during pregnancy changes the expression of cytochrome P450 in the livers of infant male mice. Biol. Pharm. Bull. 36, 649-657 (2013).
45. Kusunoki, Y. et al. Hepatic early inflammation induces downregulation of hepatic cytochrome P450 expression and metabolic activity in the dextran sulfate sodium-induced murine colitis. Eur. J. Pharm. Sci. 54, 17-27 (2014).
46. Heverin, M. et al. Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J. Lipid Res. 46, 1047-1052 (2005).
47. Fuchs, M. Bile acid regulation of hepatic physiology: III. Regulation of bile acid synthesis: past progress and future challenges. Am. J. Physiol Gastrointest. Liver Physiol 284, G551-G557 (2003).
48. de Aguiar Vallim, T. Q., Tarling, E. J. & Edwards, P. A. Pleiotropic roles of bile acids in metabolism. Cell Metab 17, 657-669 (2013).
49. Halilbasic, E., Claudel, T. & Trauner, M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J. Hepatol. 58, 155-168 (2013).
50. Tremblay-Franco, M. et al. Effect of obesity and metabolic syndrome on plasma oxysterols and fatty acids in human. Steroids 99, 287-292 (2015).
51. Faulds, M. H., Zhao, C. & Dahlman-Wright, K. Molecular biology and functional genomics of liver X receptors (LXR) in relationship to metabolic diseases. Curr. Opin. Pharmacol. 10, 692-697 (2010).
52. Bensinger, S. J. et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 134, 97-111 (2008).
53. Zelcer, N. & Tontonoz, P. Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest 116, 607-614 (2006).
54. Benned-Jensen, T. et al. Molecular characterization of oxysterol binding to the Epstein-Barr virus-induced gene 2 (GPR183). J. Biol. Chem. 287, 35470-35483 (2012).
55. Daugvilaite, V., Arfelt, K. N., Benned-Jensen, T., Sailer, A. W. & Rosenkilde, M. M. Oxysterol-EBI2 signaling in immune regulation and viral infection. Eur. J. Immunol. 44, 1904-1912 (2014).
56. Kojetin, D. J. & Burris, T. P. REV-ERB and ROR nuclear receptors as drug targets. Nat. Rev. Drug Discov. 13, 197-216 (2014).
57. Wang, Y., Kumar, N., Crumbley, C., Griffin, P. R. & Burris, T. P. A second class of nuclear receptors for oxysterols: Regulation of RORalpha and RORgamma activity by 24S-hydroxycholesterol (cerebrosterol). Biochim. Biophys. Acta 1801, 917-923 (2010).
58. Alhouayek, M., Masquelier, J., Cani, P. D., Lambert, D. M. & Muccioli, G. G. Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6. Proc. Natl. Acad. Sci. USA 110, 17558-17563 (2013).
59. Geurts, L. et al. Adipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota. Nat. Commun. 6, 6495 (2015).